Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen

Free article

Comment

Karl S Peggs et al. Blood. 2002.

Free article

. 2002 Jun 15;99(12):4642-3; author reply 4643-4.

doi: 10.1182/blood.v99.12.4642.

No abstract available

Comment on

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. Kottaridis PD, et al. Blood. 2000 Oct 1;96(7):2419-25. Blood. 2000. PMID: 11001893 Clinical Trial.
Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.
Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW. Bolan CD, et al. Blood. 2001 Sep 15;98(6):1687-94. doi: 10.1182/blood.v98.6.1687. Blood. 2001. PMID: 11535498 Clinical Trial.